- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01877811
Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors
An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Advanced Solid Tumors
Study Overview
Detailed Description
The primary objective of Phase 1 is to determine the recommended Phase 2 dose (RP2D) of RXDX-105. The primary objective of Phase 1b is to further assess the safety profile and tolerability of RXDX-105 at the RP2D The secondary objective is to evaluate the antitumor activity of RXDX-105 at the RP2D, as assessed by objective response rate (ORR) (complete response [CR] or partial response [PR]) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in patients with advanced solid tumors with RET or BRAF mutations or rearrangements.
The RP2D has been determined and Phase 1 portion of the study is now closed to new patient enrollment.
Phase 1 b is open and enrolling patients with solid tumors harboring a RET rearrangement or mutation, or a BRAF rearrangement or mutation. Additionally, patients with Squamous NSCLC and lung adenocarcinomas with other alterations than RET or BRAF such as KRAS mutations, etc. will also be enrolled. Approximately 90 patients will be enrolled in Phase 1b.
Each phase of this study will consist of a 28-day screening period. Patients will be treated in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment. Patients in Phase 1 and 1b will be followed for 6 months after the last dose of study treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States
- City of Hope
-
Irvine, California, United States
- University of California Irvine College of Medicine
-
San Diego, California, United States
- University of California San Diego Moores Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, United States
- Lombardi Comprehensive Cancer Center, Georgetown
-
-
Florida
-
Sarasota, Florida, United States
- Florida Cancer Center
-
-
Georgia
-
Athens, Georgia, United States
- University Cancer & Blood Center, LLC
-
-
Massachusetts
-
Boston, Massachusetts, United States
- Massachusetts General Hospital/Beth Israel Deaconess Med. Ctr./Dana Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, United States
- Henry Ford Health System
-
Detroit, Michigan, United States
- Karmanos Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, United States
- Washington University
-
-
New York
-
New York, New York, United States
- Memorial Sloan Kettering Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center
-
-
Texas
-
Houston, Texas, United States
- University of Texas MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, United States
- University of Washington, Seattle Cancer Care Alliance
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for Phase 1b:
Patients must have histologically or cytologically confirmed advanced solid tumors with a histology and/or molecular alteration of interest as defined in Section 4, detected by a CLIA-certified or equivalently accredited diagnostic laboratory
• Squamous NSCLC and Non-squamous NSCLC (no known RET alterations or BRAF V600E mutations) patients must have archival tissue available for analysis by Ignyta; all other patients must send tissue to Ignyta, if tissue is available
Prior Treatment:
- Patients with BRAF V600E mutations must be TKI-naïve; any number of other prior therapies are allowed
- NSCLC patients with RET alterations who have had a prior RET inhibitor or are RET inhibitor-naïve will be enrolled; (any number of other prior therapies are allowed); all other histologies with RET alterations must be RET inhibitor-naïve
- Patients with Squamous NSCLC and Non-squamous NSCLC (no known RET alterations or BRAF V600E mutations) may have had prior TKIs and any number of other prior therapies
- Measurable disease according to RECIST v1.1 for all patients except patients with RET altered tumors; patients with RET altered tumors must have evaluable disease, but are not required to have measurable disease
- Patients with treated, stable CNS metastases, including leptomeningeal carcinomatosis are allowed. The use of seizure prophylaxis is allowed. Patients requiring steroids must be at a stable or decreasing dose for at least 2 weeks prior to the start of RXDX-105 treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Able to ingest oral medication
- Other inclusion criteria apply
Exclusion Criteria for Phase 1b:
- Treated with systemic anticancer therapy or an investigational agent within 2 weeks or 5 half-lives, whichever is shorter, prior to start of study drug treatment (4 weeks for antibody therapy and immunotherapy, and 2 weeks for bevacizumab in colon cancer patients)
- Major surgery 21 days or less prior to starting study drug or has not recovered from adverse effects of such therapy
- Radiotherapy within 2 weeks prior to start of study drug treatment (palliative radiation or stereotactic radiosurgery within 7 days prior to start of study treatment). Patients must have recovered from all radiotherapy-related toxicities
- History of non-pharmacologically induced prolonged QTc interval (e.g., repeated demonstration of a QTc interval > 500 milliseconds from ECGs performed at least 24 hours apart)
- Major active infection requiring parenteral antibiotics
- Severe or unstable medical condition, such as congestive heart failure (New York Heart Association [NYHA] Class III or IV), ischemic heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as well as an uncontrolled cardiac arrhythmia requiring medication (≥ Grade 2, according to NCI CTCAE v4.03), myocardial infarction within 6 months prior to starting study treatment, or any other significant or unstable concurrent medical illness that in the opinion of the Investigator would preclude protocol therapy
- History of other previous cancer that would interfere with the determination of safety or efficacy of RXDX-105 with respect to the qualifying solid tumor malignancy
- Known infection with human immunodeficiency virus (HIV) and active hepatitis B or hepatitis C
- Current participation in another clinical study of an investigational agent, vaccine, or device. Concomitant participation in observational studies is acceptable
- Presence of a significant gastrointestinal disorder that, in the opinion of the Investigator or Sponsor, could interfere with absorption of RXDX-105 (e.g., malabsorption syndrome, gastrointestinal surgery)
- Known hypersensitivity to any of the components of RXDX-105
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RXDX-105
|
During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day. During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Dose Limiting Toxicities
Time Frame: Approximately 12 months
|
From signing of the informed consent up to approximately 12 months
|
Approximately 12 months
|
Phase 1: Occurrence of Adverse Events
Time Frame: Approximately 12 months
|
From signing of the informed consent up to approximately 12 months
|
Approximately 12 months
|
Phase 1b: Occurrence of Adverse Events
Time Frame: Approximately 12 months
|
To further assess the safety profile and tolerability of RXDX-105 at the RP2D
|
Approximately 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Maximum observed plasma drug concentration (Cmax)
Time Frame: Day 1 to Day 16
|
Day 1 to Day 16
|
|
Phase 1: Time of maximum observed plasma drug concentration (tmax)
Time Frame: Day 1 to Day 16
|
Day 1 to Day 16
|
|
Phase 1: Area under the plasma drug concentration versus time curve from time 0 to infinity (AUC0-∞)
Time Frame: Day 1 to Day 16
|
Day 1 to Day 16
|
|
Phase 1: Area under the plasma drug concentration versus time curve from time 0 to the last measureable drug concentration (AUC0-t)
Time Frame: Day 1 to Day 16
|
Day 1 to Day 16
|
|
Phase 1: Area under the plasma drug concentration versus time curve from time 0 to 24 hours after study drug administration (AUC0-24)
Time Frame: Day 1 to Day 16
|
Day 1 to Day 16
|
|
Phase 1: Terminal elimination rate constant (λz)
Time Frame: Day 1 to Day 16
|
Day 1 to Day 16
|
|
Phase 1: Terminal elimination half-life (t1/2)
Time Frame: Day 1 to Day 16
|
Day 1 to Day 16
|
|
Phase 1: Apparent clearance of study drug from plasma (CL/F)
Time Frame: Day 1 to Day 16
|
Day 1 to Day 16
|
|
Phase 1b: Objective Response Rate
Time Frame: Approximately 12 months
|
Objective response rate is defined as the proportion of patients with advanced solid tumors achieving best overall response of complete response (CR), or partial response (PR), as assessed using RECIST v1.1
|
Approximately 12 months
|
Phase 1b: Duration of Objective Response
Time Frame: Approximately 12 months
|
The duration of objective response is defined as the time interval from the date of first documented response (CR or PR) to disease progression or death, whichever occurs first
|
Approximately 12 months
|
Phase 1b: Clinical Benefit Rate
Time Frame: Approximately 12 months
|
Clinical benefit rate is defined as the proportion of patients achieving a complete response (CR), partial response (PR) or stable disease (SD) for 6 months
|
Approximately 12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RXDX-105-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
NeuPharma, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States
Clinical Trials on RXDX-105
-
Hoffmann-La RocheNo longer availableCancers With RET AlterationsUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedOvarian Cancer | Non Small Cell Lung Cancer | RET Gene Mutation | BRAF Gene MutationUnited States
-
Hoffmann-La RocheTerminated
-
Hoffmann-La RocheTerminatedAdvanced or Metastatic Solid TumorsUnited States
-
Draeger Medical Systems, Inc.CompletedHyperbilirubinemia | Neonatal JaundiceCanada
-
Beijing InnoCare Pharma Tech Co., Ltd.Completed
-
AegisCN LLCDuke Clinical Research Institute; PharPoint Research, Inc.CompletedIntracerebral HemorrhageUnited States
-
Noema Pharma AGCompletedChildhood-Onset Fluency DisorderUnited States, Australia